GenSight Biologics publie ses résultats financiers consolidés estimés pour l'année 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Source: Businesswire
Financial Results Overview: GenSight Biologics reported estimated consolidated financial results for 2024, showing a significant reduction in operational losses from €29.7 million in 2023 to €15.8 million in 2024, alongside a net loss decrease from €26.2 million to €14 million.
Future Outlook and Challenges: The company is focusing on securing financing to extend its cash runway beyond April 2025, while addressing regulatory inquiries regarding its LUMEVOQ® program and preparing for potential funding needs before the second half of 2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
